Emerging therapies for osteoporosis

Bibliography

• Consensus development conference: diagnosis,prophylaxis, and treatment of osteoporosis. Am. J. Med. (1993) 94:646–650.
   PubMed Web of Science ®Google Scholar
• ••Describes recommendations and guidelines for manage-ment of osteoporosis.
   Google Scholar
• KANIS JA, MELTON LJ 3RD, CHRISTIANSEN C, et al.: The diagnosis of osteoporosis. J. Bone Miner. Res. (1994) 9:1137–1141.
   PubMed Web of Science ®Google Scholar
• ••Describes criteria for diagnosis of osteoporosis.
   Google Scholar
• BAUER DC, SKLARIN PM, STONE KL, et al.: Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures. J. Bone Miner. Res. (1999) 14:1404–1410.
   PubMed Web of Science ®Google Scholar
• MELTON LJ 3RD: How many women have osteoporosis now J. Bone Miner. Res. (1995) 10:175–177.
   PubMed Web of Science ®Google Scholar
• MELTON LJ 3RD, KAN SH, FRYE MA, et al.: Epidemiology of vertebral fractures in women. Am. J. Epidemiol. (1989) 129:1000–1011.
   PubMed Web of Science ®Google Scholar
• JENSEN GF, CHRISTIANSEN C, BOESEN J, et al: Epidemi-ology of postmenopausal spinal and long bone fractures. A unifying approach to postmenopausal osteoporosis. Olin. Orthop. Rel. Res. (1982) 166:75–81.
   PubMedGoogle Scholar
• O'NEILL TW, FELSENBERG D, VARLOW J, et al: The prevalence of vertebral deformity in European men and women: the European vertebral osteoporosis study. J. Bone Miner. Res. (1996) 11:1010–1018.
   PubMed Web of Science ®Google Scholar
• COOPER C, O'NEILL T, SILMAN A: The epidemiology of vertebral fractures. European vertebral osteoporosis study group. Bone (1993) 14\(Suppl. 1):S89–S97.
   PubMedGoogle Scholar
• BARRETT-CONNOR E: The economic and human costs of osteoporotic fracture. Am. J. Med. (1995) 98(Suppl. 2A):S3–S8.
   Google Scholar
• RAY NF, CHAN JK, THAMER M, et al.: Medical expendi-tures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J. Bone Miner. Res. (1997) 12:24–35.
   PubMed Web of Science ®Google Scholar
• CUMMINGS SR, RUBIN SM, BLACK D: The future of hip fractures in the United States. Numbers, costs, and potential effects of postmenopausal estrogen. Clin. Orthop. Rel. Res. (1990) 252:163–166.
   PubMed Web of Science ®Google Scholar
• EDDY DM, JOHNSTON CC: Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Introduction. Osteoporos. Int. (1998) 8:S7–S80.
   PubMed Web of Science ®Google Scholar
• THE WRITING GROUP FOR THE PEPI TRIAL: Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. J. Am. Med. Assoc. (1996) 276:1389–1396.
   PubMed Web of Science ®Google Scholar
• ••Report of clinical trial demonstrating an increase in BMD byoestrogen replacement therapy.
   Google Scholar
• SPEROFF L, ROWAN J, SYMONS J, et al.: The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. J. Am. Med. Assoc. (1996) 276:1397–1403.
   PubMed Web of Science ®Google Scholar
• HULLEY S, GRADY D, BUSH T, et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) research group. J. Am. Med. Assoc. (1998) 280:605–613.
   PubMed Web of Science ®Google Scholar
• ••Report suggests lack of efficacy in secondary prevention ofcoronary diseases despite a decrease in lipid profile.
   Google Scholar
• BERESFORD SA, WEISS NS, VOIGT LF, et al. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet (1997) 349:458–461.
   PubMed Web of Science ®Google Scholar
• COLDITZ GA Hormones and breast cancer: evidence and implications for consideration of risks and benefits of hormone replacement therapy. J. Women's Health (1999) 8:347–357.
   PubMed Web of Science ®Google Scholar
• •A review of risk and benefit of HRT suggesting a causal relationship between oestrogen use and breast cancer in postmenopausal women.
   Google Scholar
• WALSH BW, KULLER LH, WILD RA, et al.: Effects ofraloxifene on serum lipids and coagulation factors in healthy postmenopausal women. J. Am. Med. Assoc. (1998) 279:1445–1451.
   PubMed Web of Science ®Google Scholar
• ETTINGER B, BLACK DM, MITLAK BH, et al: Reduction ofvertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investiga-tors. J. Am. Med. Assoc. (1999) 282:637–645.
   Google Scholar
• ••References [19,20] describe interim 3-year results of Phase IIItrial with raloxifene demonstrating significant reduction in vertebral fractures and breast cancer risk.
   Google Scholar
• CUMMINGS SR, ECKERT S, KRUEGER KA, et al.: The effect of raloxifene on risk of breast cancer in postmeno-pausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. J. Am. Med. Assoc. (1999) 281:2189–2197.
   PubMed Web of Science ®Google Scholar
• ••References [19,20] describe interim 3-year results of Phase IIItrial with raloxifene demonstrating significant reduction in vertebral fractures and breast cancer risk.
   Google Scholar
• BEARDSWORTH SA, KEARNEY CE, PURDIE DW Preven-tion of postemenopausal bone loss at lumbar spine and upper femur with tibolone: a two year randomised controlled trial. Br. J. Obstel Gynecol (1999) 106:678–683.
   PubMedGoogle Scholar
• GENAZZANI AR, BENDEK-JASZMANN LJ, HART DM, et al: Org OD 14 and the endometrium. Maturitas (1991) 13:243–251.
   PubMed Web of Science ®Google Scholar
• ADACHI JD, BENSEN WG, BROWN J, et al: Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl. J. Med. (1997) 337:382–387.
   PubMed Web of Science ®Google Scholar
• CUMMINGS SR, BLACK DM, THOMPSON DE, et al.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. J. Am. Med. Assoc. (1998) 280:2077–2082.
   PubMed Web of Science ®Google Scholar
• ••Results of clinical trial demonstrating a significant reductionin risk of vertebral fractures among osteoporotic women but not among women with higher BMD.
   Google Scholar
• HARRIS ST, WATTS NB, GENANT HK, et al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteopo-rosis - a randomized controlled trial. J. Am. Med. Assoc. (1999) 282:1344–1352.
   PubMed Web of Science ®Google Scholar
• •Demonstrates that risedronate therapy is effective and well-tolerated in the treatment of women with established postmenopausal osteoporosis.
   Google Scholar
• LIN JH: Bisphosphonates: a review of their pharma-cokinetic properties. Bone (1996) 18:75–86.
   PubMed Web of Science ®Google Scholar
• MURRILLS RJ, SHANE E, LINDSAY R, et al: Bone resorp-tion by isolated human osteoclasts in vitro: effects of calcitonin. J. Bone Miner. Res. (1989) 4:259–68.
   PubMed Web of Science ®Google Scholar
• •The report of potent inhibition of bone resorption by osteoclasts in response to calcitonin.
   Google Scholar
• PEICHL P, RINTELEN B, KUMPAN W, et al.: Increase of axial and appendicular trabecular and cortical bone density in established osteoporosis with intermittent nasal salmon calcitonin therapy. Gynecol. Endocrinol (1999) 13:7–14.
   PubMed Web of Science ®Google Scholar
• KOHNO T, MURASUGI N, SAKURAI H, et al: A sandwichtransfer enzyme immunoassay for salmon calcitonin: determination of the bioavailability of intranasal salmon calcitonin in human. J. Chn. Lab. Anal. (1997) 11:380–387.
   PubMed Web of Science ®Google Scholar
• NOTOYA K, YOSHIDA K, TSUKUDA R, et al: Effect of ipriflavone on expression of markers characteristic of the osteoblast phenotype in rat bone marrow stromal cell culture. J. Bone Miner. Res. (1994) 9:395–400.
   PubMed Web of Science ®Google Scholar
• GENNARI C, ADAMI S, AGNUSDEI D, et al: Effect of chronic treatment with ipriflavone in postmeno-pausal women with low bone mass. Calcif Tissue mt. (1997) 61 (Suppl. 1):S19–S22.
   PubMedGoogle Scholar
• CHAPUY MC, ARLOT ME, DUBOEUF F, et al: Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl. J. Med. (1992) 327:1637–1642.
   PubMed Web of Science ®Google Scholar
• MAMELLE N, MEUNIER PJ, DUSAN R, et al.: Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet (1988) 2:361–365.
   PubMed Web of Science ®Google Scholar
• •References [33,34] demonstrate the controversial aspect of fluoride therapy.
   Google Scholar
• RIGGS BL, HODGSON SF, O'FALLON WM, et al.: Effect of fluoride treatment on the fracture rate in postmeno-pausal women with osteoporosis. N Engl. J. Merl. (1990) 322:802–809.
   PubMed Web of Science ®Google Scholar
• •References [33,34] demonstrate the controversial aspect of fluoride therapy.
   Google Scholar
• KLEERKOPER M: Fluoride: the verdict is in, but the controversy lingers. J. Bone Miner. Res. (1996) 11:565–567.
   PubMed Web of Science ®Google Scholar
• Smith R (Ed.), . Royal College of Physicians of London, London, UK (1990):125–133.
   Google Scholar
• JOHNSTON CC, JR., MILLER JZ, SLEMENDA CW, et al.: Calcium supplementation and increases in bone mineral density in children. N Engl. J. Med. (1992) 327:82–87.
   PubMed Web of Science ®Google Scholar
• YAFFE K, SAWAYA G, LIEBERBURG I, et al.: Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. J. Am. Merl. Assoc. (1998) 279:688–695.
   PubMed Web of Science ®Google Scholar
• OGER E, SCARABIN PY: Assessment of the risk for venous thromboembolism among users of hormone replacement therapy. Drugs Aging (1999) 14:55–61.
   PubMed Web of Science ®Google Scholar
• GENANT HK, LUCAS J, WEISS S, et al: Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. Arch. Int. Merl. (1997) 157:2609–2615.
   PubMed Web of Science ®Google Scholar
• STUDD J, ARNALA I, KICOVIC PM, et al: A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures. Obstet. Gynecol. (1998) 92:574–579.
   PubMed Web of Science ®Google Scholar
• SAAG KG, EMKEY R, SCHNITZER TJ, et al: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N. Engl. J. Med. (1998) 339:292–299.
   PubMed Web of Science ®Google Scholar
• ORWOLL E, ETTINGER M, WEISS S, et al: Alendronatetreatment of osteoporosis in men. J. Bone Miner. Res. (1999) 14 (Suppl. 1):S184.
   Google Scholar
• ETTINGER B, PRESSMAN A, SCHEIN J, et al.: Alendronateuse among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J. Managed Care Pharm. (1998) 4:488–492.
   Google Scholar
• ••The report of adverse gastrointestinal effects of alendronateand non-compliance due to strict dosing requirements.
   Google Scholar
• WATTS NB, HARRIS ST, GENANT HK, et al: Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N. Engl. J. Med. (1990) 323:73–79.
   PubMed Web of Science ®Google Scholar
• PETER CP, KINDT MV, MAJKA JA: Comparative study of bisphosphonates to damage gastric mucosa of rats. Dis. Sci. (1999) 43:1009–1015.
   Web of Science ®Google Scholar
• DAVIS SM, BROWN TR: Use of etidronate in the treatment of postmenopausal osteoporosis. J. Pharm. Technol (1994) 10:102–105.
   Google Scholar
• FILIPPONI P, PEDETTI M, FEDELI L, et al.: Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy. J. Bone Miner. Res. (1995) 10:697–703.
   PubMed Web of Science ®Google Scholar
• OVERGAARD K, RIIS BJ, CHRISTIANSEN C, et al: Effect of salcatonin given intranasally on early postmeno-pausal bone loss. Br. Med. J. (1989) 299:477–479.
   PubMed Web of Science ®Google Scholar
• ADAMI S, BUFALINI L, CERVETTI R, et al.: Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over two years. Osteoporos. Int. (1997) 7:119–125.
   PubMed Web of Science ®Google Scholar
• Mosaic Study #9 on osteoporosis (1998).
   Google Scholar
• KUIPER G, ENMARK E, PELTOHUIKKO M, et al.: Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA (1996) 93:5925–5930.
   PubMed Web of Science ®Google Scholar
• MOSSELMAN S, POLMAN J, DIJKEMA R: ER-13 - Identifica-tion and characterization of a novel human estrogen receptor. FEBS Lett. (1996) 392:49–53.
   PubMed Web of Science ®Google Scholar
• TREMBLAY GB, TREMBLAY A, COPELAND NG, et al.: Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor p. Mol. Endocrinol. (1997) 11:353–365.
   PubMed Web of Science ®Google Scholar
• FLEISCH HA: Bisphosphonates - preclinical aspects anduse in osteoporosis. Ann. Merl. (1997) 29:55–62.
   PubMed Web of Science ®Google Scholar
• SEEMAN E, TSALAMANDRIS C, BASS S, et al.: Present andfuture of osteoporosis therapy. Bone (1995) 17 (Suppl. 2):S23–S29.
   Web of Science ®Google Scholar
• DEMPSTER DW, COSMAN F, PARISIEN M, et al.: Anabolic actions of parathyroid hormone on bone. Endocrinol Rev. (1993) 14:690–709.
   PubMed Web of Science ®Google Scholar
• COSMAN F, LINDSAY R: Is parathyroid hormone a therapeutic option for osteoporosis - a review of the clinical evidence. Cakif Tissue Int. (1998) 62:475–480.
   PubMed Web of Science ®Google Scholar
• Pharmaceutical and Biotechnology Bulletin: Merrill Lynch (1998).
   Google Scholar
• MARIE PJ, ARLOT ME, BRAILLON P, et al.: A new agent containing strontium (5 12911) increases bone mass in normal and ovariectomized rats. J. Bone Miner. Res. (1991) 6:S249.
   Web of Science ®Google Scholar
• KE HZ, CHEN HK, SIMMONS HA, et al: Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model. Bone (1997) 20:31–39.
   PubMed Web of Science ®Google Scholar
• ROSATI RL, JARDINE PD, CAMERON KO, et al: Discoveryand preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J. Med. Chem. (1998) 41:2928–2931.
   PubMed Web of Science ®Google Scholar
• TAKEUCHI M, SAKAMOTO S, YOSHIDA M, et al.: Studieson novel bone resorption inhibitors. I. Synthesis and pharmacological activities of aminomethylene-bisphosphonate derivatives. Chem. Pharm. Bull. (1993) 41:688–93.
   PubMed Web of Science ®Google Scholar
• THIEBAUD D, BURCKHARDT P, KRIEGBAUM H, et al.: Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am. J. Merl. (1997) 103:298–307.
   PubMed Web of Science ®Google Scholar
• •Demonstrates that bolus iv. injection of ibandronate results in significant increase in BMD in osteoporotic postmeno-pausal women.
   Google Scholar
• GEDDES AD, SOUZA D, EBETINO FH, et al.: Bisphos-phonates: structure-activity relationships and therapeutic implications. Bone Miner. (1994) 8:265–306.
   Google Scholar
• RAVN P, CLEMMESEN B, RIIS BJ, et al.: The effect on bone mass and bone markers of different doses of ibandronate - a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis - a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone (1996) 19:527–533.
   PubMed Web of Science ®Google Scholar
• ARDEN-CORDONE M, SIRIS ES, LYLES KW, et al.: Antire-sorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone. Calcif Tissue Int. (1997) 60:415–8.
   PubMed Web of Science ®Google Scholar
• GREEN JR, MULLER K, JAEGGI KA: Preclinical pharma-cology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J. Bone Miner. Res. (1994) 9:745–51.
   PubMed Web of Science ®Google Scholar
• KUDO M, ABE T, MOTOIE H, et al.: Pharmacological profile of new bisphosphonate, 1-hydroxy-2-(imidazo[1,2-A]pyridin-3-yl)ethane-1,1-bis-(phosphonic acid). Bone Miner. (1992) 17:170.
   Google Scholar
• FIDIA ADVANCED BIOPOLYMERS' (FAB) HYALURON RESEARCH: Scrip (1993) 1855:11.
   Google Scholar
• ROCHIRA M, MIGLIETTA MR, RICHARDSON JL, et al.: Novel vaginal delivery systems for calcitonin. 2. Preparation and characterization of Hyaff® microspheres containing calcitonin. Int. J. Pharm. (1996) 144:19–26.
   Google Scholar
• RICHARDSON JL, RAMIRES PA, MIGLIETTA MR, et al.: Novel vaginal delivery systems for calcitonin. 1. Evaluation of Hyaff calcitonin microspheres in rats. Int. J. Pharm. (1995) 115:9–15.
   Web of Science ®Google Scholar
• MAKINO Y, DOHI M, NISHIBE Y, et al.: Powder prepara-tion of salmon calcitonin for nasal administration. Pharm. Res. (1995) 12:S313.
   PubMed Web of Science ®Google Scholar
• ADACHI JD, BENSEN WG, BELL MJ, et al.: Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. Br. J. Rheumatol (1997) 36:255–259.
   PubMedGoogle Scholar
• REGINSTER JY, JUPSIN I, DEROISY R, et al.: Prevention ofpostmenopausal bone loss by rectal calcitonin. Calcif Tissue Int. (1995) 56:539–542.
   PubMed Web of Science ®Google Scholar
• KOLLERUP G, HERMANN AP, BRIXEN K, et al.: Effects ofsalmon calcitonin suppositories on bone mass and turnover in established osteoporosis. Calcif Tissue Int. (1994) 54:12–15.
   PubMed Web of Science ®Google Scholar
• MAZZANTINI M, DI MUNNO 0, PARDINI N, et al.: Treatment of postmenopausal osteoporosis with salmon calcitonin suppositories. Ital. J. Miner. Electro-lyte Metab. (1996) 10:23–28.
   Web of Science ®Google Scholar
• MINEGISHI T, NAKAO Y, URADA K, et al.: Pharma-cological studies of avicatonin ([Asul,71-chicken calcitonin). Effects of avicatonin on experimental osteoporosis in rats. Jpn. Pharmacol Ther. (1994) 22:151–156.
   Google Scholar
• HAKEDA Y, KURIHARA N, ARM Y, et al.: Effects of avicatonin (synthetic [Asul,7] chicken calcitonin) on bone resorption. Avicatonin inhibits generation of multinucleated osteoclast-like cells and their activi-ties. Jpn. Pharmacol. Ther. (1994) 22:143–150.
   Google Scholar
• HIDAKA S, ABE K, TAKEUCHI Y, et al.: Inhibition of the formation of oral calcium phosphate precipitates: Beneficial effects of Chinese traditional (kampo) medicines. J. Periodont. Res. (1993) 28:27–34.
   PubMed Web of Science ®Google Scholar
• ITABASHI A, NEMOTO K, TSUBOI M, et al.: A newly formulated eel calcitonin nasal spray (NDE-1003) has remarkable absorbability and inhibits osteoclastic bone resorption in human. J. Bone Miner. Res. (1997) 12:T546.
   Web of Science ®Google Scholar
• DEROISY R, COLLETTE J, CHEVALLIER T, et al.: Effects oftwo 1-year calcium and vitamin D3 treatments on bone remodeling markers and femoral bone density in elderly women. Curr. Ther. Res. Clin. Exp. (1998) 59:850–862.
   Web of Science ®Google Scholar
• KIRIYAMA T, OKAMOTO S, ERMA E, et al.: Effect of ahighly potent fluoro analog of 1,25-dihydroxyvitamin D3 on human bone-derived cells. Endocrinol. (1991) 128:81–6.
   PubMed Web of Science ®Google Scholar
• HARADA M, MIYAHARA T, MIYATA M, et al.: Effects on cultured neonatal mouse calvaria of 1 alpha, 25-dihydroxyvitamin D3 26,26,26,27,27,27-hexa-fluor o-1 alpha,25-dihydroxyvitamin-D3 and 26,26,26,27,27,27-hexafluoro-1alpha,235,25-trihydroxyvitamin D3. Bone Miner. (1992) 18:41–49.
   PubMedGoogle Scholar
• OKUMURE H, YAMAMURO T, HIGUCHI S, et al.: 26,27-Hexafluoro-1,25-dihydroxyvitamin D3 (F6-1,25(OH)2D3) prevents osteoporosis induced by immobilization combined with ovariectomy in the rat. Bone Miner. (1990) 9:101–109.
   PubMedGoogle Scholar
• NISHII Y, SATO K, KOBAYASHI T: The development of vitamin D3 analogues for the treatment of osteopo-rosis. Osteoporos. Int. (1993) 3 (Suppl. 1):190–193.
   PubMedGoogle Scholar
• TSURUKAMI H, NAKAMURA T, SUZUKI K, et al. A novelsynthetic vitamin D analogue, 2 beta-(3-hydroxy-propoxyl1 alpha, 25-dihydroxyvitamin D3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats. Catch'. Tissue Int. (1994) 54:142–9.
   PubMed Web of Science ®Google Scholar
• FUJITA T, INOUE T, MORII H, et al.: Effect of an intermit-tent weekly dose of human parathyroid hormone (1-34) on osteoporosis: a randomized double-masked prospective study using three dose levels. Osteoporosis. mt. (1999) 9:296–306.
   PubMed Web of Science ®Google Scholar
• ••Results from clinical trial demonstrating that weekly lowdose PTH(1–34) injection increases lumbar BMD in osteoporotic patients.
   Google Scholar
• HODSMAN AB, DROST D, FRAHER LJ, et al.: The additionof a raloxifene analog (LY117018) allows for reduced PTH(1-34) dosing during reversal of osteopenia in ovariectomized rats. J. Bone Miner. Res. (1999) 14:675–679.
   PubMed Web of Science ®Google Scholar
• LINDSAY R, HODSMAN A, GENANT H, et al: A random-ized controlled multi-center study of 1–84 hPTH for treatment of postmenopausal osteoporosis. J. Bone Miner. Res. (1998) 23 (Suppl. 5):S175.
   Google Scholar
• ••Results from clinical trial indicating that daily Sc. injection ofPTH(1–84) increases lumbar BMD in osteoporotic women.
   Google Scholar
• Hoechst and Biopharm sign bone morphogenetic protein (BMP) deal. Scrip (1994) 1975:11.
   Google Scholar
• SIMONET WS, LACEY DL, DUNSTAN CR, et al.: Osteoprote-gerin - a novel secreted protein involved in the regula-tion of bone density. Cell (1997) 89:309–319.
   PubMed Web of Science ®Google Scholar
• •Reference [92,93] report identification of OPG/OCIF as a negative regulator of osteoclast differentiation and activity in vitro and in vivo.
   Google Scholar
• YASUDA H, SHIMA N, NAKAGAWA N, et al.: Identity ofosteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG) - a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinol. (1998) 139:1329–1337.
   PubMed Web of Science ®Google Scholar
• •Reference [92,93] report identification of OPG/OCIF as a negative regulator of osteoclast differentiation and activity in vitro and in vivo.
   Google Scholar
• BEKKER PJ, HOLLOWAY D, NAKANISHI A, et al.: Osteoprotegerin (OPG) has potent and sustained anti-resorptive activity in postmenopausal women. J. Bone Miner. Res. (1999) 14 (Suppl. 1):S180.
   Google Scholar
• •Results from Phase I trial with OPG demonstrating safety and a reduction in bone resorption marker.
   Google Scholar
• BAGI CM, BROMMAGE R, DELEON L, et al.: Benefit of systemically administered rhIGF-I and rhIGF-I/IGEBP-3 on cancellous bone in ovariecto-mized rats. J. Bone Miner. Res. (1994) 9:1301–1312.
   PubMed Web of Science ®Google Scholar
• BAGI CM, DELEON E, BROMMAGE R, et al: Systemic administration of rhIGF-I or rhIGF-I/IGEBP-3 increases cortical bone and lean body mass in ovariec-tomized rats. Bone (1995) 16\(Suppl. 4):S263–S269.
   Web of Science ®Google Scholar
• MEUNIER PJ, SLOSMAN D, DELMAS PD, et al: Strontium ranelate as a treatment of vertebral osteoporosis. J. Bone Miner. Res. (1997) 12:S129.
   Web of Science ®Google Scholar
• HORTON MA: The cc,63 integrin `vitronectin receptor'. Int. J. Biochem. Cell Biol. (1997) 29:721–725.
   PubMed Web of Science ®Google Scholar
• NESBITT S, NESBIT A, HELFRICH M, et al.: Biochemicalcharacterization of human osteoclast integrins. Osteoclasts express av133, a2131, and avBi integrins. Biol. Chem. (1993) 268:16737–16745.
   Web of Science ®Google Scholar
• ENGLEMAN VW, NICKOLS GA, ROSS FP, et al.: A peptidomimetic antagonist of the avp3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J. Clin. Invest. (1997) 99:2284–2292.
   PubMed Web of Science ®Google Scholar
• LARK MW, STROUP GB, HVVANG SM, et al.: Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis. J. Pharmacol. Exp. Ther. (1999) 291:612–617.
   PubMed Web of Science ®Google Scholar
• •The report of an orally-active vitronectin receptor antagonist that inhibits bone resorption.
   Google Scholar
• STROUP GB, LARK MW, MILLER WH, et al.: SB267268, a potent antagonist of the osteoclast vitronectin receptor, inhibits bone resorption in an estrogen deficient state in a non-human primate. J. Bone Miner. Res. (1999) 14 (Suppl. 1):S411.
   Google Scholar
• MCHUGH KP, HODIVALA-DILKE K, CHENG S-L et al.: The 133 integrin knockout mouse is osteosclerotic and has dysfunctional osteoclasts. Bone (1998) 23 (Supp.1):S190.
   Google Scholar
• SCHVARTZ I, SEGER D, SHALTIEL S: Vitronectin. Int. J. Biochem. Cell Biol. (1999) 31:539–544.
   PubMed Web of Science ®Google Scholar
• INAOKA T, BILBE G, ISHIBASHI 0 et al.: Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. Biochem. Biophys. Res. Commun. (1995) 206:89–96.
   PubMed Web of Science ®Google Scholar
• •References [105-107] report the identification and cloning of cathepsin K from human osteoclasts.
   Google Scholar
• BROMME D, OKAMOTO K, WANG BB, et al.: Human cathepsin 02, a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expres-sion of human cathepsin 02 in Spodoptera frugiperda and characterization of the enzyme. J. Biol. Chem. (1996) 271:2126–2632.
   PubMed Web of Science ®Google Scholar
• •References [105-107] report the identification and cloning of cathepsin K from human osteoclasts.
   Google Scholar
• DRAKE FH, DODDS RA, JAMES IE, et al.: Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J. Biol. Chem. (1996) 271:12511–12516.
   PubMed Web of Science ®Google Scholar
• •References [105-107] report the identification and cloning of cathepsin K from human osteoclasts.
   Google Scholar
• GARNERO P, BOREL 0, BYRJALSEN I, et al.: The collageno-lytic activity of cathepsin K is unique among mammalian proteinases. J. Biol. Chem. (1998) 273:32347–32352.
   PubMed Web of Science ®Google Scholar
• LJUSBERG J, DODDS RA, LARK MW, et al.: Tartarate-resistant acid phosphatase is proteolytically cleaved in vivo by cathepsin K. J. Bone Miner. Res. (1999) 14 (Suppl. 1):S358.
   Google Scholar
• XIA L, KILB J, WEX H, et al.: Localization of rat cathepsin K in osteoclasts and resorption pits: inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl sulfones. Biol. Chem. (1999) 380:679–687.
   PubMed Web of Science ®Google Scholar
• GELB BD, SHI GP, CHAPMAN HA, et al.: Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science (1996) 273:1236–1238.
   PubMed Web of Science ®Google Scholar
• ••References [111,112] links mutations in cathepsin K genethat results in cathepsin K deficiency and osteopetrotic phenotype and validates cathepsin K as a therapeutic target.
   Google Scholar
• JOHNSON MR, POLYMEROPOULOS MH, VOS HL, et al.: A nonsense mutation in the cathepsin K gene observed in a family with pycnodysostosis. Genome Res. (1996) 6:1050–1055.
   PubMed Web of Science ®Google Scholar
• ••References [111,112] links mutations in cathepsin K genethat results in cathepsin K deficiency and osteopetrotic phenotype and validates cathepsin K as a therapeutic target.
   Google Scholar
• SAFTIG P, HUNZIKER E, WEHMEYER 0 et al: Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl. Acad. Sci. USA (1998) 95:13453–13458.
   PubMed Web of Science ®Google Scholar
• ••References [113,114] reports the characterisation ofcathepsin k null mice as osteopetrotic and validates cathepsin K as a therapeutic target.
   Google Scholar
• GOWEN M, LAZNER F, DODDS R, et al.: Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J. Bone Miner. Res. (1999) 14:1654–1663.
   PubMed Web of Science ®Google Scholar
• ••References [113,114] reports the characterisation ofcathepsin k null mice as osteopetrotic and validates cathepsin K as a therapeutic target.
   Google Scholar
• THOMPSON SK, HALBERT SM, BOSSARD MJ, et al.: Design of potent and selective human cathepsin K inhibitors that span the active site. Proc. Natl. Acad. Sci. USA (1997) 94:14249–14254.
   PubMed Web of Science ®Google Scholar
• •References [115,116] reports the development of inhibitors of cathepsin K and L that inhibit bone resorption in vivo.
   Google Scholar
• YASUMA T, OI S, CHOH N, et al.: Synthesis of peptide aldehyde derivatives as selective inhibitors of human cathepsin L and their inhibitory effect on bone resorp-tion. J. Med. Chem. (1998) 41:4301–4308.
   PubMed Web of Science ®Google Scholar
• •References [115,116] reports the development of inhibitors of cathepsin K and L that inhibit bone resorption in vivo.
   Google Scholar
• LAITALA T, VAANANEN HK: Inhibition of bone resorp-tion in vitro by antisense RNA and DNA molecules targeted against carbonic anhydrase II or two subunits of vacuolar 11±-ATPase. J. Clin. Invest. (1 99 4) 93:2311-2318.
   Google Scholar
• FARINA C, GAGLIARDI S: Selective inhibitors of the osteoclast vacuolar proton ATPase as novel bone antiresorptive agents. Drug Disc. Today (1999) 4:163–172.
   PubMed Web of Science ®Google Scholar
• VISENTIN L, VALENTE M, DODDS RA, et al.: SB-242784, a selective inhibitor of the osteoclast v-11±-ATPase, prevents bone loss in ovariectomized rats. Bone (1998) 23:S181.
   PubMed Web of Science ®Google Scholar
• •This report demonstrates that osteoclast v-H+-ATPase inhibitor prevents ovariectomy-induced bone loss.
   Google Scholar
• GAGLIARDI S, NADLER G, CONSOLANDI E, et al.: 5 -(5, 6 -Dichloro- 2 -indoly1)- 2 -methoxy-2,4-pentadienamides - novel and selective inhibitors of the vacuolar HtATPase of osteoclasts with bone antiresorptive activity. J. Med. Chem. (1 9 98) 41:1568-1573.
   Google Scholar
• SORIANO P, MONTGOMERY C, GESKE R, et al.: Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell (1991) 64:693–702.
   PubMed Web of Science ®Google Scholar
• ••First report of an unexpected bone phenotype in src nullmice.
   Google Scholar
• BOYCE BF, YONEDA T, LOWE C, et al.: Requirement of pp60c-Src expression for osteoclasts to form ruffled borders and resorb bone in mice. J. Clin. Invest. (1992) 90:1622–1627.
   PubMed Web of Science ®Google Scholar
• MISSBACH M, JESCHKE M, FEYEN J, et al.: A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone (1999) 24:437–449.
   Google Scholar
• •References [123,124] report the development of inihibitors of Src that inihibit bone resorption in vitro and in vivo.
   Google Scholar
• GAMSE R, WIDLER L, MISSBACH M, et al.: NVP-AAK980, a novel phenylamino-2-alkylamino-purine derivative, potently inhibits the tyrosine kinase Src and bone resorption. J. Bone Miner. Res. (1999) 14\(Suppl. 0):5487.
   Google Scholar
• •References [123,124] report the development of inihibitors of Src that inihibit bone resorption in vitro and in vivo.
   Google Scholar
• ALOBEIDI FA, WU JJ, LAM KS: Protein tyrosine kinases - structure, substrate specificity, and drug discovery. Biopolymers (1998) 47:197–223.
   PubMed Web of Science ®Google Scholar
• DUONG LT, LAKKAKORPI PT, NAKAMURA I, et al: Pyk2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activated by ligation of alpha(v) beta3 integrin, and phosphorylated by Src kinase. J. Clin. Invest. (1998) 102:881–892.
   PubMed Web of Science ®Google Scholar
• LAKKAKORPI PT, NAKAMURA I, NAGY RM, et al.: Stable association of PYK2 and p130(Cas) in osteoclasts and their co-localization in the sealing zone. J. Biol. Chem. (1999) 274:4900–4907.
   PubMed Web of Science ®Google Scholar
• DUONG LT, RODAN GA: Integrin-mediated signaling in the regulation of osteoclast adhesion and activation. Front. Biosci. (1998) 3:757–768.
   PubMedGoogle Scholar
• COBB MH, GOLDSMITH EJ: How MAP kinases are regulated. J. Biol. Chem. (1995) 270:14843–14846.
   PubMed Web of Science ®Google Scholar
• LEE JC, LAYDON JT, MCDONNELL PC, et al.: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature (1994) 372:739–746.
   PubMed Web of Science ®Google Scholar
• ••This report describes the identification of p38 MAP kinase asa target of pyridinyl imidazole class of compounds that inhibit inflammatory cytokine production from monocytes.
   Google Scholar
• GOWEN M, WOOD DD, IHRIE EJ, et al.: An interleukin 1-like factor stimulates bone resorption in vitro. Nature (1983) 306:378–380.
   PubMed Web of Science ®Google Scholar
• •First report of IL-1 as a potent stimulator of bone resorption.
   Google Scholar
• KIMBLE RB, VANNICE JL, BLOEDOW DC, et al.: Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. J. Clin. Invest. (1994) 93:1959–1967.
   PubMed Web of Science ®Google Scholar
• MANOLAGAS SC: Role of cytokines in bone resorption. Bone (1995) 1 7 (Suppl. 2):63S–67S.
   Google Scholar
• BADGER AM, BRADBEER JN, VOTTA B, et al. Pharmacological profile of SB 19203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharmacol. Exp. Ther. (1996) 279:1453–1461.
   Google Scholar
• •References [133,134] report the inhibition of bone resorption by selective p38 MAP kinase inhibitors.
   Google Scholar
• BRADBEER JN, STROUP GB, HOFFMAN SJ, et al.: An orally active inhibitor of cytokine synthesis prevents bone loss in the ovariectomized rat. J. Bone Miner. Res. (1996) 11 (Suppl. 1):S125.
   PubMed Web of Science ®Google Scholar
• •References [133,134] report the inhibition of bone resorption by selective p38 MAP kinase inhibitors.
   Google Scholar
• HENRY JR, RUPERT KC, DODD JH, et al.: 6-Amino-2-(4-fluoropheny1)-4-methoxy-3-(4-pyridy0-1H-pyrrolo[2,3- b]pyridine (RWJ 68354): a potent and selective p38 kinase inhibitor. J. Med. Chem. (1998) 41:4196–4198.
   PubMed Web of Science ®Google Scholar
• DE LASZLO SE, VISCO D, AGARWAL L, et al.: Pyrroles and other heterocycles as inhibitors of p38 kinase. Bioorg. Med. Chem. Lett. (1998) 8:2689–2694.
   PubMed Web of Science ®Google Scholar
• LEE JC, KASSIS S, KUMAR S, et al: p38 mitogen-activated protein kinase inhibitors - Mechanism and therapeutic potentials. Pharmacol. Ther. (1999) 82:389–397.
   PubMed Web of Science ®Google Scholar
• AURON PE: The interleukin 1 receptor: ligand interac-tions and signal transduction. Cytokine Growth Factor Rev. (1998) 9:221–237.
   PubMed Web of Science ®Google Scholar
• PACIFICI R, VANNICE JL, RIFAS L, et al: Monocytic secretion of interleukin-1 receptor antagonist in normal and osteoporotic women: effects of menopause and estrogen/progesterone therapy. J. Endocrinol. Metab. (1993) 77:1135–1141.
   Google Scholar
• SUNYER T, LEWIS J, OSDOBY P: Estrogen decreases the steady state levels of the IL-1 signaling receptor (Type 0 while increasing those of the IL-ldecoy receptor (Type II) mRNA in human osteoclast-like cells. J. Bone Miner. Res. (1997) 12 (Suppl. 1):S135.
   Google Scholar
• LORENZO JA, NAPRTA A, RAO Y, et al.: Mice lacking the Type I interleukin-1 receptor do not lose bone mass after ovariectomy. Endocrinology (1998) 139:3022–3025.
   PubMed Web of Science ®Google Scholar
• •This report demonstrates that IL-1 signaling through Type I IL-1R is essential for bone resorption.
   Google Scholar
• TSUDA E, GOTO M, MOCHIZUKI S, et al.: Isolation of a novel cytokine from human fibroblasts that specifi-cally inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun. (1997) 234:137–142.
   PubMed Web of Science ®Google Scholar
• BUCAY N, SAROSI I, DUNSTAN CR, et al.: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. (1998) 12:1260–1268.
   PubMed Web of Science ®Google Scholar
• LACEY DL, TIMMS E, TAN HL, et al.: Osteoprotegerin ligand is a cytokine that regulates osteoclast differen-tiation and activation. Cell (1998) 93:165–176.
   PubMed Web of Science ®Google Scholar
• •References [145-147] describes the identification of an osteoclast differentiation factor which turns out to be identical to RANKL and TRANCE.
   Google Scholar
• YASUDA H, SHIMA N, NAKAGAWA N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin osteoclastogenesis-Inhibitory factor and is identical to TRANCE/RANKL. Proc. NatL Acad. Sci. USA (1998) 95:3597–3602.
   Google Scholar
• •See annotation to [145].
   Google Scholar
• WONG BR, JOSIEN R, CHOI Y: TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J. Leukoc. Biol. (1999) 65:715–724.
   PubMed Web of Science ®Google Scholar
• •See annotation to [145].
   Google Scholar
• HSU HL, LACEY DL, DUNSTAN CR, et al.: Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA (1999) 96:3540–3545.
   PubMed Web of Science ®Google Scholar
• MORONY S, CAPPARELLI C, LEE R, et al.: A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-lp, TNFa, PTH, PTHrP, and 1,25(011)2 03. J. Bone Miner. Res. (1999) 14:1478–1485.
   PubMed Web of Science ®Google Scholar
• EMERY JG, MCDONNELL P, BURKE MB, et al.: Osteoprote-gerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. (1998) 273:14363–14367.
   PubMed Web of Science ®Google Scholar
• KONG YY, YOSHIDA H, SAROSI I, et al.: OPGL is a key regulator of osteoclastogenesis, lymphocyte develop-ment and lymph-node organogenesis. Nature (1999) 397:315–323.
   PubMed Web of Science ®Google Scholar
• NEMETH EF: Calcium receptors as novel drug targets. In: Principles of Bone Biology. Bilezekian JP, Raisz LG, Rodan G (Eds.) Academic Press, San Diego, USA (1996):1019–1035.
   Google Scholar
• GOWEN M, STROUP GB, DODDS RA, et al.: Antagonism of the parathyroid Ca" receptor with a calcilytic compound induces PTH secretion and stimulates bone formation in osteopenic rats. (1999) (Submitted).
   Google Scholar
• GOWEN M, STROUP GB, BRADBEER JN, et al.: An antago-nist of the parathyroid cell Ca receptor stimulates PTH secretion and bone turnover in osteopenic ovariectomized rats. Bone (1998) 23 (Suppl. 5):S163.
   PubMedGoogle Scholar
• •First demonstration that a CaR antagonist increases indices of bone formation in ovariectomised rats.
   Google Scholar
• NEMETH EF, FOX J, DELMAR EG, et al.: Stimulation of parathyroid hormone secretion by a small molecule antagonist of the calcium receptor. Bone (1998) 23 (Suppl. 5):S156.
   Google Scholar
• •Demonstration that a CaR antagonist stimulates endogenous PTH release in normal rats.
   Google Scholar
• SCHMITT JM, HWANG K, WINN SR, et al.: Bone morpho-genetic proteins: an update on basic biology and clinical relevance. J. Orthop. Res. (1999) 17:269–278.
   PubMed Web of Science ®Google Scholar
• NOTOYA K, NAGAI H, ODA T, et al.: Enhancement of osteogenesis in vitro and in vivo by a novel osteoblast differentiation promoting compound, TAK-778. J. Pharmacol. Exp. Ther. (1999) 290:1054–64.
   PubMed Web of Science ®Google Scholar
• •Identification of a small molecule which enhances osteogenesis in vitro and stimulates bone formation in vivo in bony defect and osteotomy models.
   Google Scholar
• WANG GJ, CHUNG KC, SHEN WJ: Lipid clearing agents in steroid-induced osteoporosis. J. Formos. Med. Assoc. (1995) 94:589–592.
   PubMed Web of Science ®Google Scholar
• CUI QJ, WANG GJ, SU CC, et al: Lovastatin prevents steroid induced adipogenesis and osteonecrosis. Orthop. Rel. Res. (1997) :8–19.
   Google Scholar
• FISHER JE, ROGERS MJ, HALASY JM, et al.: Alendronate mechanism of action: geranylgeraniol, an interme-diate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc. Natl. Acad. ScL USA (1999) 96:133–138.
   PubMed Web of Science ®Google Scholar
• SATO T, MORITA I, MUROTA S: Involvement of choles-terol in osteoclast-like cell formation via cellular fusion. Bone (1998) 23:135–140.
   PubMed Web of Science ®Google Scholar
• MUNDY G, GARRETT R, HARRIS S, et al.: Stimulation of bone formation in vitro and in rodents by statins. Science (1999) 286:1946–1949.
   PubMed Web of Science ®Google Scholar
• ••Demonstration that statins stimulate bone formation in vitroand in vivo, which is associated with increased expression of BMP–2.
   Google Scholar
• BAUER DC, MUNDY GR, JAMAL SA, et al: Statin use, bone mass and fracture: an analysis of two prospective studies. J. Bone Miner. Res. (1999) 14 (Suppl. 1):S179.
   Google Scholar
• TAM CS, AKHTER MP, JOHNSTON E, et al.: A new peptide for bone formation with its actions related to exercise. Bone (1998) 23 (Suppl. 5):5613.
   Google Scholar